AP NEWS
Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019

Affimed N.V.May 16, 2019

Heidelberg, Germany, May 16, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it will host a conference call on Wednesday, May 22, 2019 at 8:30 a.m. ET to discuss its first quarter 2019 financial results and recent corporate developments.

The conference call will be available via phone and webcast. To access the call, please dial +1 631 510 7495 for U.S. callers, or +44 (0) 2071 928000 for international callers, and reference conference ID 1083705 approximately 15 minutes prior to the call.

An audio webcast of the conference call can be accessed in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts/. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company that engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat cancers. For more information, please visit www.affimed.com.

Affimed Investor Contact:Gregory Gin, Head of Investor RelationsE-Mail: IR@affimed.com

Affimed Media Contact:Anca Alexandru, Head of Communications, EU IRE-Mail: media@affimed.com

All contents © copyright 2019 The Associated Press. All rights reserved.